Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.
Introduction of drug eluting stents (DES) during percutaneous coronary interventions significantly reduces the rate of angiographic restenosis, target lesion and vessel revascularization. In spite of these benefits, other clinical hard end points such as death or myocardial infarction were not reduced and, furthermore, new concerns associated with the presence of late and very late stent thrombosis have been raised. The requirement of long-term dual antiplatelet therapy is another limitation associated with DES. Conversely, in this decade, other options to DES have been simultaneously discussed in observational and randomized studies. Several registries and randomized trials using the systemic approach with anti-inflammatory, immunosuppressive or antiplatelet therapies have been identified and discussed in this manuscript. In spite of all randomized studies with oral therapies in the bare metal stent (BMS) era demonstrating positive reductions in coronary restenosis, this practice has not been introduced clinically. Furthermore, a recent randomized trial comparing oral sirolimus plus BMS versus DES demonstrated that the first approach was cost saving and of comparable efficacy to DES. Conclusive evidence of high incidence of late and very late stent thrombosis with DES, together with clinical limitations for its widespread use, has opened up a large opportunity to search for alternative therapies in coronary restenosis prevention.
Rodriguez
Alfredo E
AE
Otamendi Hospital, Post Graduate School of Medicine, Cardiac Unit, Buenos Aires, Argentina. rodrigueza@sanatorio-otamendi.com.ar
D015906:Angioplasty, Balloon, Coronary; D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography / Q000379:methods; D023903:Coronary Restenosis / Q000209:etiology; D003328:Coronary Thrombosis / Q000517:prevention & control*; D054855:Drug-Eluting Stents / Q000639:trends; D004562:Electrocardiography; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011474:Prosthesis Design; D012042:Registries; D020123:Sirolimus / Q000009:adverse effects*; D015607:Stents / Q000009:adverse effects*; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D050257:Tubulin Modulators; D020123:Sirolimus